🔗 Share this article

While the United States proceeds with unprecedented changes to its vaccination guidelines, a particular individual appears unexpectedly: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by questioning COVID-19 vaccines during the pandemic and has zeroed in on potential fatalities following Covid vaccination in her brief tenure at the FDA.

Scheduled Overhauls to Pediatric Immunization Program

Health officials were set to reveal major revisions to the pediatric vaccination calendar in December, aligning the US with the Danish national calendar, it is understood – a major change that would put the US out of step with a large portion of the international standard with insufficient data for public health gain. This reveal has been pushed back until the coming year.

In place of the director of the vaccine center, Dr. Høeg is listed to address the audience at the event. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the division this year.

A New Direction at the Regulatory Body

Høeg's temporary position might represent a tighter collaboration between the drug and biologics divisions as Dr. Høeg and Prasad consolidate power at the agency – and it signals a renewed priority upon reevaluating previously authorized immunizations at the FDA.

The new acting director has often pushed for halting specific pediatric vaccine recommendations in the US in order to be more similar to Denmark, a society with universal health coverage and a number of inhabitants approximately the size of the state of Wisconsin.

In her initial comments, she has continued to focus on vaccination policy – usually the responsibility of Dr. Prasad, head of the FDA’s CBER – as opposed to pharmaceutical oversight.

Questions Over Qualifications

Dr. Høeg has no apparent experience in pharmaceutical research, oversight or leadership, which has been typical for previous directors of the biologics center. She has worked at the FDA as a key advisor to the commissioner and the vaccine center since earlier this year.

“She appears not to have the necessary background” for overseeing the drug-regulation department, stated Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in leading a sizeable institution. She has no expertise in drug approvals.”

Former commissioners of CBER would “understand legal statutes and the underlying principles of drug development”, said Dr. Janet Woodcock. “Frankly, she lacks the kind of background that former directors who headed CBER have had.”

CDER has an vast portfolio at the FDA, Woodcock emphasized.

“Many people just zeroes in on the new drug program, but the generic program clears a multitude of generic medications. There’s a biosimilars program, non-prescription drug unit and other areas, and all of those need to be managed,” she noted. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a significant management element to the role, which supervises in excess of 5,000 staff members. “It is a enormous leadership role, if you perform it correctly,” she said.

Official Statement and Contentious Programs

Regarding concerns about Høeg’s credentials and whether this assignment indicates more teamwork among agency officials on immunizations, a press secretary responded that the “concerns rely on flawed assumptions”.

“Her resume aligns with the duties of her job,” the official explained, noting the period Dr. Høeg spent advising the agency head on “medication safety and regulatory science, including computational safety modeling and immunization monitoring”.

As acting director, Høeg inherits the agency head's new priority voucher program, a contentious one-day therapy clearance system that allegedly worried her predecessors. “By what process are these drugs being chosen for this fast-track system? Who takes the calls?” Howard questioned. “There is a lot of confidentiality happening at the regulatory body right now.”

Overall, he said, “the FDA seems to be moving towards laxer regulations of pharmaceuticals, with the exception of shots.”

Established Past Work on Vaccines

With immunizations, Høeg has a more documented, if concerning, track record, Howard said. She authored a research paper using non-validated crowd-sourced reports to estimate the rate of myocarditis following Covid vaccination. She counseled the state of Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccinations are more dangerous than they are.

Part of her “desired changes” for the current federal leadership encompassed revising rules for novel immunizations and discontinuing “non-essential” immunizations, she said after the election on a audio program. At the agency, Høeg has according to sources proposed preventing young men from receiving COVID-19 vaccines.

“She is an complete true believer who begins with her beliefs and tailors the evidence to retrofit the data in a very misleading, untruthful fashion,” Howard argued.

Taking Control and a “Revenge Tour”

Høeg aligned with fellow contrarians, {like|